Trial NCT03715166

View at ClinicalTrials.gov 
Org. Study IDs: CL3-95008-001
Secondary IDs: 2017-004419-38

Last trial update was posted on 2022-03-29

MeSH Interventions

Bumetanide

MeSH Conditions

Autism Spectrum Disorder

Other Conditions

Autism Spectrum Disorder (ASD)

Stopping Reasons

The 6-month efficacy analysis did not show any significant difference between bumetanide versus placebo in the treatment of ASD in the overall studied population. No unexpected safety concerns were identified.

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID